系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种慢性炎症性自身免疫性疾病,可影响多个器官,包括皮肤、关节、中枢神经系统和肾脏等,其发病因素包括环境、免疫和激素因素以及遗传易感性等。TLR/MyD88信号通路是调控先天免疫...系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种慢性炎症性自身免疫性疾病,可影响多个器官,包括皮肤、关节、中枢神经系统和肾脏等,其发病因素包括环境、免疫和激素因素以及遗传易感性等。TLR/MyD88信号通路是调控先天免疫反应和相关的炎症反应的重要通路之一,参与SLE疾病的发生发展。本文总结了TLR/MyD88通路的构成、激活途径,重点介绍了该信号通路在SLE中在免疫细胞中的相关机制,并总结了近年来针对TLR和MyD88的拮抗剂及其潜在的临床应用。Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that can affect multiple organs, including the skin, joints, central nervous system, and kidneys. The pathogenic factors include environmental, immune, and hormonal factors, as well as genetic susceptibility. The TLR/MyD88 signaling pathway is one of the important pathways that regulate innate immune responses and related inflammatory responses, and is involved in the occurrence and development of systemic lupus erythematosus (SLE). This article summarizes the composition and activation pathways of the TLR/MyD88 pathway, focusing on the relevant mechanisms of this signaling pathway in immune cells in SLE, and summarizes the antagonists against TLR and MyD88 in recent years and their potential clinical applications.展开更多
文摘系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种慢性炎症性自身免疫性疾病,可影响多个器官,包括皮肤、关节、中枢神经系统和肾脏等,其发病因素包括环境、免疫和激素因素以及遗传易感性等。TLR/MyD88信号通路是调控先天免疫反应和相关的炎症反应的重要通路之一,参与SLE疾病的发生发展。本文总结了TLR/MyD88通路的构成、激活途径,重点介绍了该信号通路在SLE中在免疫细胞中的相关机制,并总结了近年来针对TLR和MyD88的拮抗剂及其潜在的临床应用。Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that can affect multiple organs, including the skin, joints, central nervous system, and kidneys. The pathogenic factors include environmental, immune, and hormonal factors, as well as genetic susceptibility. The TLR/MyD88 signaling pathway is one of the important pathways that regulate innate immune responses and related inflammatory responses, and is involved in the occurrence and development of systemic lupus erythematosus (SLE). This article summarizes the composition and activation pathways of the TLR/MyD88 pathway, focusing on the relevant mechanisms of this signaling pathway in immune cells in SLE, and summarizes the antagonists against TLR and MyD88 in recent years and their potential clinical applications.
